Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.
Sponsor: Center for Clinical and Basic Research (CCBR A/S).
This PHASE1 trial investigates Bone Degenerative Changes and Degenerative Disorder of Bone and is currently completed. Center for Clinical and Basic Research (CCBR A/S). leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
May 2017 — Oct 2017 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Clinical and Basic Research (CCBR A/S).
- Medtronic
- Northern Orthopaedic Division, Denmark
For direct contact, visit the study record on ClinicalTrials.gov .